Stockreport

Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Fulcrum Therapeutics, Inc.  (FULC) 
Last fulcrum therapeutics, inc. earnings: 3/5 07:00 am Check Earnings Report
PDF CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on develop [Read more]